Low-dose naltrexone (LDN) does appear to reduce inflammation, though the evidence is still building. Multiple small clinical trials show it lowers key inflammatory markers in the blood and improves symptoms in several inflammatory conditions, including fibromyalgia, Crohn’s disease, and multiple sclerosis. The mechanism is distinct from conventional anti-inflammatory drugs: rather than blocking pain signals or suppressing the immune system broadly, LDN targets a specific part of the body’s immune response in the central nervous system.
How LDN Reduces Inflammation
Naltrexone is an opioid-blocking drug typically prescribed at 50 mg for addiction treatment. At much lower doses, usually between 1 and 6 mg, it behaves differently. LDN appears to work by blocking a receptor called TLR4, which sits on immune cells in the brain and spinal cord called microglia. These cells act as the nervous system’s first responders. When TLR4 is activated, microglia release a cascade of inflammatory chemicals that increase nerve sensitivity and contribute to chronic pain. By blocking this receptor, LDN can quiet that inflammatory response at its source.
This is fundamentally different from how standard anti-inflammatory drugs like ibuprofen or naproxen work. Those drugs block enzymes involved in producing pain and inflammation throughout the body. LDN instead modulates the immune system’s behavior in the central nervous system, which is why it’s sometimes described as an immunomodulator rather than a traditional anti-inflammatory. This distinction matters because it means LDN may help with conditions driven by neuroinflammation, where the nervous system itself is inflamed, rather than only addressing swelling in joints or tissues.
What Happens to Inflammatory Markers
One of the strongest pieces of evidence for LDN’s anti-inflammatory effect comes from direct measurement of inflammatory chemicals in the blood. In a study of fibromyalgia patients, eight weeks of LDN significantly reduced plasma levels of 17 different inflammatory markers. These included several that play central roles in chronic inflammation: IL-6 dropped from 15.0 to 9.7 pg/mL, and TNF-alpha fell from 146.9 to 138.4 pg/mL. Both changes were statistically significant. The study also found reductions in a wide range of other signaling molecules involved in immune activation and tissue inflammation.
Separately, research on fibromyalgia has found that a blood marker called erythrocyte sedimentation rate (ESR), a general indicator of inflammation in the body, can predict who will respond well to LDN. Patients with higher baseline inflammation were more likely to experience a 30% or greater reduction in symptoms. This supports the idea that LDN’s benefits are tied specifically to its anti-inflammatory action rather than some other pain-relief mechanism.
Evidence in Crohn’s Disease
Crohn’s disease involves chronic inflammation of the digestive tract, and LDN has shown some of the most encouraging results here. In a pilot study of 47 patients who started LDN, 74.5% experienced clinical improvement and 25.5% achieved clinical remission by week 12. A follow-up randomized, placebo-controlled trial in 34 patients found an 88% response rate in the LDN group compared to 40% in the placebo group after 12 weeks. Perhaps more importantly, 33% of LDN patients achieved endoscopic remission, meaning visible healing of the intestinal lining, compared to just 8% on placebo.
A smaller trial in 12 pediatric patients with inflammatory bowel disease showed similar patterns: 67% had clinical improvement and 25% reached remission after eight weeks. These are small studies, and a larger multicenter trial is underway, but the consistency of results across different patient groups is notable. Researchers behind the larger trial estimated that LDN could produce mucosal healing rates of 25% compared to 5% for placebo in mild to moderate Crohn’s disease.
Evidence in Fibromyalgia and MS
Fibromyalgia is increasingly understood as a condition involving neuroinflammation, which makes it a logical target for LDN. Systematic reviews of the available trials have found some evidence that LDN reduces pain and improves quality of life in fibromyalgia patients, though the studies remain small. The reduction in pro-inflammatory cytokines described above came from fibromyalgia research, providing a biological explanation for the symptom improvements patients report.
In multiple sclerosis, another condition driven by inflammation attacking the nervous system, at least three clinical trials have found that LDN increases quality of life and significantly improves mental health in patients with relapsing-remitting or secondary progressive MS. Animal studies showed that LDN reduced the activation of inflammatory brain cells, decreased demyelination (the stripping of nerve insulation that causes MS symptoms), and limited neuronal damage. Long-term follow-up in MS patients found that LDN did not worsen inflammatory disease progression based on MRI readings, and patients reported stable or decreased fatigue levels over sustained treatment periods.
Side Effects Are Typically Mild
LDN is generally well tolerated. The most commonly reported side effects across fibromyalgia trials were vivid dreams, transient insomnia, and headache. These tend to occur early in treatment and often resolve on their own or with a slight dose reduction. One dose-response study found that reducing the dose to 3.0 mg per day minimized vivid dreams and headaches. Other reported side effects include fatigue, mild nausea, abdominal discomfort, and occasionally diarrhea, though these were described as mild and tolerable. Several studies reported no side effects at all related to LDN.
How LDN Is Taken
LDN is not available as a standard off-the-shelf prescription at typical pharmacies. Because the doses are so small (often between 1 and 4.5 mg, compared to the standard 50 mg naltrexone tablet), it usually needs to be prepared by a compounding pharmacy. The tiny amount of active ingredient is too small to measure or handle on its own, so it’s mixed with inactive fillers to create a capsule or liquid you can dose accurately. For people with chemical sensitivities, capsules tend to contain the fewest additives, and sublingual liquid formulations have the least preservatives overall.
Dosing typically starts very low and increases gradually. One well-documented protocol begins at 0.1 mg per day and increases by 0.1 mg every couple of days, allowing patients to assess how they feel at each level before moving up. This slow titration continues until symptoms improve or until reaching a ceiling of around 6 mg per day, at which point the trial is usually stopped if there’s been no benefit. Many practitioners and studies use a simpler approach, starting at 1.5 mg and working up to 4.5 mg over several weeks.
What the Evidence Does and Doesn’t Show
The biological case for LDN as an anti-inflammatory is fairly strong. It blocks a known inflammatory receptor on immune cells in the nervous system, and measurable reductions in inflammatory markers have been documented in human blood samples. Clinical improvements in conditions defined by inflammation, particularly Crohn’s disease, add weight to this mechanism.
The main limitation is study size. Most clinical trials of LDN have involved fewer than 50 participants, and many lack placebo controls. The Crohn’s disease data is the most robust, with randomized controlled results, but even those involve small numbers. For MS, some clinical endpoints failed to show differences from placebo despite quality-of-life improvements. The overall picture is promising but preliminary: LDN likely does reduce inflammation through a specific and well-characterized mechanism, but the clinical evidence hasn’t yet reached the scale that would make it a first-line recommendation for most inflammatory conditions.
Most patients in clinical trials began noticing benefits within 8 to 12 weeks of treatment, which is the timeframe used in the majority of published studies. If you’re considering LDN, that window is a reasonable benchmark for assessing whether it’s working.